Related references
Note: Only part of the references are listed.Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study
Nobuyuki Miyasaka et al.
Modern Rheumatology (2014)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
Modern Rheumatology (2014)
A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology
Akito Takamura et al.
Modern Rheumatology (2014)
Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs
Masayoshi Harigai et al.
Modern Rheumatology (2014)
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (Phase IIIb ALLOW study)
Jeffrey Kaine et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
G. M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Subset Analysis of Patients Experiencing Clinical Events of a Potentially Immunogenic Nature in the Pivotal Clinical Trials of Tocilizumab for Rheumatoid Arthritis: Evaluation of an Antidrug Antibody ELISA Using Clinical Adverse Event-Driven Immunogenicity Testing
Kay Stubenrauch et al.
CLINICAL THERAPEUTICS (2010)
Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
Jennifer Barton
Patient Preference and Adherence (2010)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Treatment choices, preferences and decision-making by patients with rheumatoid arthritis
Frances Chilton et al.
MUSCULOSKELETAL CARE (2008)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Patient preferences in choosing anti-TNF therapies-R1
E. L. Williams et al.
RHEUMATOLOGY (2006)
Validation of a Japanese version of the Stanford health assessment questionnaire in 3,763 patients with rheumatoid arthritis
Y Matsuda et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2003)
Share Paper
